Persistent Pulmonary Hypertension of the Newborn



Persistent Pulmonary Hypertension of the Newborn


Linda J. Van Marter



I. DEFINITION.

Persistent pulmonary hypertension of the newborn (PPHN) results from disruption of the normal perinatal fetal to neonatal circulatory transition. The disorder is characterized by sustained elevation in pulmonary vascular resistance (PVR), rather than the decrease in PVR that normally occurs at birth. Survivors of PPHN are at risk for adverse sequelae including chronic pulmonary disease and neurodevelopmental disabilities. Contemporary ventilator management, treatment with inhaled nitric oxide (iNO), and extracorporeal membrane oxygenation (ECMO) have improved survival among infants with PPHN.



  • Perinatal circulatory transition. The normal perinatal circulatory transition is characterized by a rapid fall in PVR accompanying the first breath and a marked increase in systemic vascular resistance (SVR) associated with clamping of the umbilical cord. Circulating biochemical mediators released in response to increased arterial oxygen content and pH and lowered PaCO2 cause constriction of the ductus arteriosus and vasorelaxation of the pulmonary circulation. These physiologic events raise SVR relative to PVR, cause functional closure of the foramen ovale, and signal the normal perinatal transition in pulmonary and systemic circulations. PPHN physiology mimics the fetal circulation in which PVR exceeds SVR and right-to-left hemodynamic shunting occurs through the foramen ovale and/or ductus arteriosus. Thus, PPHN also has been called “persistent fetal circulation.” Before birth, this circulatory configuration results in systemic delivery of oxygenated blood from the placental circulation; in postnatal life, it causes diminished pulmonary perfusion and systemic hypoxemia.


II. EPIDEMIOLOGIC ASSOCIATIONS.

PPHN occurs at a rate of 1 to 2 per 1,000 live births and is most common among full-term and postterm infants. Perinatal risk factors reported in association with PPHN include meconium-stained amniotic fluid and maternal conditions such as fever, anemia, and pulmonary disease. Case-control studies of risk factors for PPHN suggest associations between PPHN and a number of antenatal and perinatal factors, including maternal diabetes mellitus, urinary tract infection during pregnancy, selective serotonin reuptake inhibitors (SSRIs), aspirin, nonsteroidal anti-inflammatory drug consumption during pregnancy, and cesarean section delivery. Although mechanisms of antenatal pathogenesis remain uncertain, there are a number of perinatal and neonatal conditions that have well-established links with PPHN.




  • Severe fetal hypoxemia (“asphyxia”) is the most common associated diagnosis. Some speculate that prolonged fetal stress and hypoxemia lead to remodeling and abnormal muscularization of pulmonary arterioles. Acute birth asphyxia also causes release of vasoconstricting humoral factors and suppression of pulmonary vasodilators, thus contributing to pulmonary vasospasm.


  • Pulmonary parenchymal diseases, including surfactant deficiency, pneumonia, and aspiration syndromes, such as meconium aspiration, are also associated with increased risk of PPHN. In most such cases, the pulmonary hypertension is reversible, suggesting a vasospastic contribution; however, concomitant pulmonary vascular remodeling cannot be excluded. The risk of pulmonary hypertension appears to be greater when the fetus is of more advanced gestational age, suggesting that the stage of pulmonary vascular development might play a role in susceptibility to PPHN.


  • Abnormalities of pulmonary development contribute structurally to PPHN, either by pruning of the vascular tree, as occurs in congenital diaphragmatic hernia, Potter syndrome, and other forms of pulmonary parenchymal hypoplasia, or malalignment of pulmonary veins and arteries, as is seen in alveolar capillary dysplasia.


  • Myocardial dysfunction, myocarditis, intrauterine constriction of the ductus arteriosus, and several forms of congenital heart disease, including left-and rightsided obstructive lesions, can lead to pulmonary hypertension.


  • Pneumonia and/or sepsis of bacterial or viral origin can initiate PPHN. Underlying pathophysiologic mechanisms that contribute to pulmonary hypertension in this clinical setting include suppression of endogenous nitric oxide (NO) production, endotoxin-mediated myocardial depression, and pulmonary vasoconstriction associated with release of thromboxanes.


  • Although familial recurrence of PPHN is uncommon, genetic predisposition might influence PPHN risk. Infants with PPHN have low plasma levels of arginine and NO metabolites and have a greater likelihood of specific polymorphisms at position 1,405 of the carbamoyl-phosphate synthetase gene. Further, although no specific polymorphisms of NO synthase genes have been reported in association with PPHN, diminished endothelial NO synthase (eNOS) expression has been observed among infants with PPHN. In addition, several recent case reports have linked a mutation of the ABCA3 gene with PPHN.


III. PATHOLOGY AND PATHOPHYSIOLOGY



  • Pulmonary vascular remodeling is pathognomonic of idiopathic PPHN and has been reported among a series of infants with fatal PPHN. Abnormal muscularization of the normally nonmuscular intra-acinar arteries, with increased medial thickness of the larger muscular arteries, results in a decreased cross-sectional area of the pulmonary vascular bed and elevated PVR. Mechanisms leading to the vascular remodeling of PPHN are under investigation. One possible stimulus to pulmonary vascular remodeling is fetal hypoxemia. Humoral growth factors released by hypoxia-damaged endothelial cells promote vasoconstriction and overgrowth of the pulmonary vascular muscular media. Laboratory and limited clinical data suggest that vascular changes might also occur following fetal exposure to nonsteroidal anti-inflammatory agents that cause constriction of the fetal ductus arteriosus and associated fetal pulmonary overcirculation.



  • Pulmonary hypoplasia affects both alveolar and pulmonary arteriolar development. It may be seen as an isolated anomaly or with congenital diaphragmatic hernia, oligohydramnios syndrome, renal agenesis (i.e., Potter syndrome), or remodeling or vasoconstriction of impaired fetal breathing.


  • Reversible pulmonary vasospasm is the likely pathophysiologic mechanism among infants with nonfatal PPHN. The underlying disease process, the associated conditions, and the developmental stage of the host each appear to modulate the pathophysiologic response. Hypoxia induces profound pulmonary vasoconstriction, and this response is exaggerated by acidemia. Neural and humoral vasoactive substances each might contribute to the pathogenesis of PPHN, the response to hypoxemia, or both. These include factors associated with platelet activation and production of arachidonic acid metabolites. Suppression of endogenous NO, prostacyclin, or bradykinin production and release of thromboxanes (A2 and its metabolite, B2) and leukotrienes (C4 and D4) appear to mediate the increased PVR seen with sepsis and hypoxemia.


  • Myocardial dysfunction with elevated PVR



    • Right ventricular (RV) dysfunction can be caused by intrauterine constriction of the ductus arteriosus, which results in altered fetal hemodynamics, postnatal pulmonary hypertension, RV failure, and an atrial right-to-left shunt. Furthermore, RV failure resulting in altered diastolic compliance causes right-to-left atrial shunting even in the absence of elevated PVR.


    • Left ventricular (LV) dysfunction causes pulmonary venous hypertension and secondary pulmonary arterial hypertension, often to suprasystemic levels, contributing to right-to-left hemodynamic shunting through the ductus arteriosus. Treating this form of pulmonary hypertension requires an approach that improves LV function, rather than simply lowering PVR.


  • Mechanical factors that influence PVR include cardiac output and blood viscosity. Low cardiac output recruits fewer pulmonary arteriolar channels and raises PVR by this mechanism as well as by its primary effect of lowering mixed venous oxygen content. Hyperviscosity, associated with polycythemia, reduces pulmonary microvasculature perfusion.


IV. DIAGNOSIS.

PPHN should be routinely considered in evaluating the cyanotic newborn.

Jun 11, 2016 | Posted by in PEDIATRICS | Comments Off on Persistent Pulmonary Hypertension of the Newborn

Full access? Get Clinical Tree

Get Clinical Tree app for offline access